{"entity":{"id":"nct06243458","kind":"trial","name":"RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms","aka":[],"tldr":"A phase 2 trial of RVU120 (SEL120) in myelodysplastic syndromes / neoplasms, run by GCP-Service International West GmbH, active and no longer recruiting.","summary":"RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms is a phase 2 interventional study registered as NCT06243458 by GCP-Service International West GmbH, with 41 participants enrolled, started 2024-09-10 and due to reach its primary completion in 2026-05. Interventions recorded: RVU120 (SEL120).","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06243458","url":"https://clinicaltrials.gov/study/NCT06243458"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["mds"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["ryvu-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06243458","phase":"2","setting":"A Phase II, Open-label, Multicenter Study of Orally Administered RVU120 for the Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms (MDS)","sponsor":"GCP-Service International West GmbH","enrolled":41,"outcomes":[]},"route":"/trials/nct06243458/","neighbours":{"cancer":[{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"company":[{"id":"ryvu-therapeutics","kind":"company","name":"Ryvu Therapeutics","route":"/companies/ryvu-therapeutics/"}]}}